Prolgolimab

N/A

Report date: 2024/08/02 17:42:19

Base Information

Drug NameProlgolimab
Drug Alias NameAnti-PD-1 monoclonal antibody (Biocad)Anti PD-1 mAbFortecaBCD-100
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody human
Mechanisms of ActionProgrammed cell death protein 1 blockers
TargetsProgrammed cell death protein 1
Therapy Area/IndicationsUterine Cervical NeoplasmsCarcinoma, Non-Small-Cell LungLung Neoplasms +[5] 
Global Approved IndicationsMelanoma
Approved Indications in ChinaN/A
Original Approved Country/TerritoryRussian Federation
Original Approved Date2020/04/01
Country/TerritoryCzechiaSlovakiaRomania +[9] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaPhase 3 Clinical
Originator CompaniesBIOCAD JSC
China Registration ClassN/A

Develop Information

Active CompaniesSPH-BIOCAD Biopharmaceuticals (SH) Co LtdBIOCAD JSCSPH-Biocad (HK) Ltd
Inactive CompaniesN/A
Active IndicationsUterine Cervical NeoplasmsCarcinoma, Non-Small-Cell LungMelanoma
Inactive IndicationsLung NeoplasmsCarcinoma, Renal Cell

Other Information

ATC CodeL01XC
Related LinksN/A